The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-09 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== Putative SLCs == Putative SLCs, also called atypical SLCs, are novel, plausible secondary active or facilitative transporter proteins that share ancestral background with the known SLCs. The atypical SLCs of MFS type can, however, be subdivided into 15 Putative MFS Transporter Families (AMTF). All the putative SLCs are plausible SLC transporters. Some are only "atypical" when it comes to their nomenclature; the genes have an SLC assignment but as an alias, and have retained their already assigned "non-SLC" gene symbol as the approved symbol. Here are some Putative SLCs listed: OCA2, CLN3, TMEM104, SPNS1, SPNS2, SPNS3, SV2A, SV2B, SV2C, SVOP, SVOPL, MFSD1, MFSD2A, MFSD2B, MFSD3, MFSD4A, MFSD4B, MFSD5, MFSD6, MFSD6L, MFSD8, MFSD9, MFSD10, MFSD11, MFSD12, MFSD13A, MFSD14A, MFSD14B, UNC93A and UNC93B1.
An open border is the deregulation and/or lack of regulation of the movement of persons between nations and jurisdictions; this does not apply to trade or movement between privately owned land areas. Most nations have open borders for travel within their nation of travel, though more authoritarian states may limit the freedom of internal movement of its citizens, as for example in the former USSR. However, only a handful of nations have deregulated open borders with other nations, an example of this being European countries under the Schengen Agreement or the open Belarus-Russia border. Open borders used to be very common among all nations, however this became less common after the First World War, which led to the regulation of open borders, making them less common and no longer feasible for most industrialised nations. Open borders are the norm for borders between subdivisions within the boundaries of sovereign states. However, some countries do maintain internal border controls (for example between the People's Republic of China mainland and the special administrative regions of Hong Kong and Macau; or between the American mainland, the unincorporated territories other than Puerto Rico, and Hawaii. Open borders are also usual between member states of federations, however, movement between member states is controlled in exceptional circumstances. Federations, confederations, and similar multinational unions typically maintain external border controls through a collective border control system.
=== Kenny Kilbane === Kenny Kilbane (Conor MacNeill) is a VP on Pierpoint's FX desk, and Yasmin's line manager. Throughout the first season, Kenny subjects Yasmin to repeated bullying and verbal abuse in the workplace, which he often blames on his alcoholism. In one case, Yasmin brings Kenny to a client dinner she arranged with her family friend Maxim Alonso, but Kenny embarrasses her when he orders a stripper to perform a lap dance on Yasmin in front of her disgusted clients. On RIF day, however, Kenny's boss Hilary Wyndham advises that Yasmin not report his behavior during her interview, suggesting that being a "team player" would help her career prospects. In series 2, Kenny returns to work following a long stint in rehab during the COVID-19 pandemic, noticeably kinder to his colleagues and vocal about his commitment to self-improvement and repentance. Yasmin, though still uncomfortable around Kenny, invites him to another client dinner, which ends up going well after Kenny and the client bond over both attending AA. When Yasmin announces her departure from the FX desk for a role in private wealth management (PWM), Kenny takes her aside and offers a sincere, tearful apology for his past behavior. Later, however, new FX hire Venetia Berens reports to Kenny that CPS client Nicole Craig sexually assaulted her, and that Yasmin dismissed her concerns. Kenny confronts Yasmin about her response, but Yasmin berates him for his hypocrisy given his own history of abusive conduct towards her, and brands him a narcissist lording his sobriety over others.
== Occurrence == Carotenoids are essential for animal health and functioning, but animals cannot produce them. Animals obtain carotenoids from their diet, with herbivores sourcing them from plants or algae, and carnivores, in turn, sourcing them from herbivores. Meso-zeaxanthin is not present in plants, except for marine species. Originally, it was suggested that meso-zeaxanthin present in humans and other vertebrates was non-dietary in origin, instead being biosynthesized in the macula (the central part of the retina) from retinal lutein (another xanthophyll carotenoid found in the human diet); this work has since been refuted. Consistent with work by Maoka et al. in 1986, Nolan et al. showed that meso-zeaxanthin is present in the skin of trout, sardine and salmon, and in the flesh of trout. In a subsequent publication, Nolan's group detected and quantified the three stereoisomers of zeaxanthin, including meso-zeaxanthin, in the flesh of two different trout species, which was the first report of concentrations of meso-zeaxanthin in habitually consumed food. Prior to this research, a publication from Khachick et al. (2002) reported that liver from Japanese quail (Coturnix japonica) and frog plasma contain meso-zeaxanthin. Meso-zeaxanthin may be generated from other carotenoids consumed by animals, as carotenoids can be interconverted for functional reasons. For example, it has been suggested that meso-zeaxanthin of trout integuments is derived from astaxanthin, and meso-zeaxanthin in primates is derived at least in part from lutein.
Sources: en.wikipedia.org
Compounds of vitamin B6 contain a pyridine ring. The actual active compound is pyridoxal phosphate. However, pyridoxal as well as pyridoxine, pyridoxamine, and their phosphates can readily be converted into pyridoxal phosphate. Consequently, all six compounds are assigned to the vitamin B6 group. In humans, pyridoxal phosphate acts as a cofactor in a very large number of biological processes, including approximately 140 known enzymatic reactions. About 4% of all cellular enzymes require pyridoxal phosphate as a cofactor. Vitamin B6 must be obtained from the diet and is found in substantial amounts in both animal and plant foods. Animal sources include fish, liver, and other offal. Plant sources include potatoes, nuts, avocados, and bananas. In plant foods, the vitamin B6 precursor pyridoxine-5'-glucoside predominates. The principal function of pyridoxal phosphate in these reactions is the stabilization of negative charges in amino compounds. Such reactions include transaminations, decarboxylations, as well as various substitution reactions and elimination reactions. Nicotinamide adenine dinucleotide (NAD) is likewise a cofactor and is essential for many redox reactions in biological systems. These include the degradation of glucose to pyruvic acid during glycolysis. NAD is also required for the citrate cycle. In addition, it acts as a regulator of transcription factors, for example in the circadian rhythm.
==== Alternative-composition breast prosthesis ==== The third category of prosthetic breast includes alternative-composition breast prostheses that featured fillers such as soy oil, polypropylene string, ox cartilage, Terylene wool, ground rubber, silastic rubber, and Teflon-silicone, which are substances harmful to the woman's body.
The simple, or top-up transfusion, is a procedure in which healthy blood cells from a donor are infused into the patient's bloodstream. This benefits by alleviating anaemia, increasing tissue oxygen levels, reducing the risk of sickling, and relieving sickling symptoms. A simple transfusion can be used to treat sickle cell disease when haemoglobin levels drop too low, or to prepare for an operation or pregnancy. It can also be used to protect against long-term complications or to reduce the risk of stroke. An exchange transfusion is a procedure in which blood is removed from the body, then processed to extract sickled cells, which are replaced by healthy red blood cells from a donor. The treated blood, including white cells and plasma, is then returned to the patient. Exchange transfusions are likely to be needed in an emergency, in severe cases of sickle cell disease, or to support a mother during pregnancy.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.